Boehringer Reflects On Resilience Of Older Therapies
As Early-Stage Oncology Pipeline Advances
The German group is investing heavily in R&D and the continued strong performance of products like Spiriva and Pradaxa is helping to pay for future innovation.
You may also be interested in...
Following in the wake of Merck & Co's acquisition of VelosBio, the German major is spending big to get hold of the Swiss oncology biotech NBE-Therapeutics which is also targeting the ROR1 protein.
Mirati’s adagrasib seems to have better efficacy data while Amgen’s sotorasib has the safety advantage, but oncologists aren’t issuing a verdict yet.
Boehringer Ingelheim intends to combine Lupin’s MEK inhibitor with its own KRAS inhibitors to target the oncogenic KRAS-RAF-MEK-ERK pathway, mutations in which drive many difficult-to-treat cancers.